Bal Pharma Ltd has introduced a range of therapeutic products in the cephalosporins segment titled Zefpod Cephalosporins account for a market size of Rs 2,330 crore growing at the rate of 12 per cent in the country.

The company is ready with its entire range, which covers Zefpod (cefpodoxime) & Zefpod-CV in three strengths consisting of Zefpod 100DT - (cefpodoxime 100 mg dispersible tablets), Zefpod 200 -(cefpodoxime 200 mg tablets), Zefpod CV - (cefpodoxime 200mg+potassium clavulanate 125mg).

The cefpodoxime market size accounts for Rs 150 crore, which is growing at 17 per cent annually. Bal Pharma is targeting at Rs 10 crore revenues in the next two years through its aggressive promotional and marketing strategies with this product alone. Zefpod will be widely promoted in General Medicine, General Surgery, Orthopedics, Gynecology, ENT & Pediatric specialties.

According to Shailesh Siroya, managing director, these new products will help to achieve a turnover target of Rs 1,000 crore by 2012.

The company is planning to file more drug master files (DMFs) in next few months. This would comprise a basket of products being required by the market as the country has an advanced healthcare system and demand for all types of pharmaceuticals is high. In the next fiscal, company is also gearing up to tap 15 new countries.

The 15-year-old Bal Pharma's strength include a range of branded formulations, APIs, generics including parenterals, intermediates and herbal drugs. The company has three manufacturing units. One is an API unit with an R & D centre. The second is a formulations plant. Both these are at Bangalore located in the Bommasandra Industrial Area. Its third unit for Parentereals is located at Pune.